Compare
Tyra Biosciences, Inc. vs Enanta Pharmaceuticals Inc vs Zevra Therapeutics, Inc. vs Nektar Therapeutics
| Latest fiscal year | Tyra Biosciences, Inc. TYRA | Enanta Pharmaceuticals Inc ENTA | Zevra Therapeutics, Inc. ZVRA | Nektar Therapeutics NKTR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $65.32M | $106.47M | $55.23M |
| Revenue growth (YoY) | n/a | -3.4% | +350.9% | -43.9% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -130.7% | -59.1% | -253.7% |
| Net margin | n/a | -125.4% | 78.2% | -297.1% |
| Net income | -$119.95M | -$81.89M | $83.23M | -$164.08M |
| EPS (Diluted) | -$2.01 | -$3.84 | $1.35 | -$9.73 |
| Operating cash flow | -$95.14M | -$19.27M | -$1.60M | -$208.51M |
| Free cash flow | -$95.28M | -$32.17M | -$2.43M | -$208.68M |
| Cash & equivalents | $77.39M | $32.30M | $62.41M | $15.12M |
| Total assets | $282.61M | $280.73M | $284.73M | $280.41M |
| Total liabilities | $23.43M | $216.01M | $130.07M | $190.57M |
| Shareholders' equity | $259.18M | $64.72M | $154.66M | $89.83M |
| Return on year-end equity | -46.3% | -126.5% | 53.8% | -182.6% |
| Shares outstanding | 53.71M | 21.39M | 56.85M | 20.38M |
Revenue, most recent five fiscal years
| Fiscal year | Tyra Biosciences, Inc. | Enanta Pharmaceuticals Inc | Zevra Therapeutics, Inc. | Nektar Therapeutics |
|---|---|---|---|---|
| Latest | n/a | $65.32M Ended 2025-09-30 | $106.47M Ended 2025-12-31 | $55.23M Ended 2025-12-31 |
| 1 year earlier | n/a | $67.64M Ended 2024-09-30 | $23.61M Ended 2024-12-31 | $98.43M Ended 2024-12-31 |
| 2 years earlier | n/a | $79.20M Ended 2023-09-30 | $27.46M Ended 2023-12-31 | $90.12M Ended 2023-12-31 |
| 3 years earlier | n/a | $86.16M Ended 2022-09-30 | $10.16M Ended 2022-12-31 | $92.06M Ended 2022-12-31 |
| 4 years earlier | n/a | $97.07M Ended 2021-09-30 | $28.65M Ended 2021-12-31 | $101.91M Ended 2021-12-31 |